Alfuzosin
As of the edition of 20 October 2026, Alfuzosin is a small molecule: marketed, first approved in 1987 (FR); acts on ADRA1A, ADRA1B and ADRA1D.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2003
- Kind
- Small molecule
- Brand name
- Uroxatral
- First approved
- 12 November 1987 (FR)
- Approvals on record
- 4 in 4 regions
- Holder of the most recent approval
- Advanz Pharma; 3 holders in all
- Registered trials
- 36, 5 stopped early
- Disease areas
- Urinary and reproductive; Pregnancy and women's health; Nervous system; Mental health; Eye; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 4 | 3 | 0 | 1 |
| Phase 1 | 3 | 1 | 0 | 0 |
| Phase 2 | 3 | 3 | 0 | 0 |
| Phase 3 | 15 | 11 | 0 | 3 |
| Phase 4 | 11 | 9 | 0 | 1 |
| All trials | 36 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Sanofi | Applicant and Lead sponsor of trials | 2001 to now |
| Advanz Pharma | Acquired holder | 2025 to now |